Long-Term Sequelae in Ebola Virus Disease Survivors Receiving Anti-Ebola Virus Therapies in the Democratic Republic of the Congo A Prospective Cohort

This prospective multicenter study of 750 Ebola survivors treated with anti-Ebola therapies evaluates the prevalence of sequelae, the incidence of recurrent episodes in the first year, and contributing factors. Nearly 90 percent of participants experienced post-Ebola sequelae during the follow-up period, most commonly neurologic, musculoskeletal, or general symptoms. They found a three-fold increase in musculoskeletal sequelae among those treated with ZMapp and neurologic sequelae were common in those treated with REGN-EB3 in comparison to those treated with remdesivir, particularly among women, older adults, and those with comorbidities.